Adult ADHD diagnoses increased by 123% between 2020 and 2025, according to a 2025 analysis in JAMA Network Open (n=5.4 million insurance claims), with the steepest rise among women aged 25-49. Dr. Stephen Faraone, a clinical psychologist at SUNY Upstate Medical University and lead author of a 2021 World Federation of ADHD consensus statement, describes the surge as the convergence of genuine under-recognition, increased awareness through social media, pandemic disruption, and broader diagnostic criteria.
ADHD was historically conceptualized as a childhood disorder of hyperactive boys. The predominantly inattentive presentation, more common in girls and women, was systematically missed. A 2020 meta-analysis in the Journal of Clinical Psychology (k=19 studies, n=5,700) estimates 50-75% of girls with ADHD are not diagnosed before age 18. Dr. Ellen Littman, a clinical psychologist specializing in gender differences in ADHD, notes that compensatory behaviors in girls — perfectionism, social masking, internalized anxiety — conceal symptoms until the demands of adulthood overwhelm coping capacity.
When pandemic-era structures disappeared, underlying executive function deficits became apparent. Remote work eliminated the environmental scaffolding — structured commutes, office routines, in-person check-ins — that had compensated for impaired self-regulation. Adults who had functioned adequately in structured settings suddenly could not manage unstructured time.
Social media presents normal human experiences as diagnostic criteria. The DSM-5 requires symptoms that are persistent, present in multiple settings, and cause clinically significant impairment. Occasional inattention is universal; ADHD is not. A 2024 survey by the American Psychological Association found that 47% of adults who self-identified as having ADHD based on social media content did not meet diagnostic thresholds on validated screening instruments.
Diagnostic rigor matters because treatment involves controlled substances. Dr. Samuele Cortese, professor of child and adolescent psychiatry at the University of Southampton, led the most comprehensive Cochrane review on ADHD medications (2022, k=24 RCTs, n=5,100), confirming medium-to-large effect sizes for methylphenidate and amphetamine formulations. However, these medications carry risks of cardiovascular elevation, appetite suppression, and potential misuse in individuals without ADHD. DEA data shows stimulant prescriptions rose 45.5% between 2012 and 2022.
The ideal diagnostic pathway, per 2023 guidelines from the American Professional Society of ADHD and Related Disorders (APSARD): thorough clinical interview, standardized rating scales (ASRS-5, CAARS-2), collateral information from a partner or family member, and screening for comorbid conditions including anxiety, depression, and sleep disorders. A 15-minute telehealth appointment followed by a prescription does not constitute adequate evaluation.